Corbus Pharmaceuticals Holdings, INC. 8-K Filing
Ticker: CRBP · Form: 8-K · Filed: Apr 7, 2026 · CIK: 0001595097
Sentiment: neutral
Filing Stats: 758 words · 3 min read · ~3 pages · Grade level 12.9 · Accepted 2026-04-07 08:15:07
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CRBP The Nasdaq Capital M
Filing Documents
- crbp-20260401.htm (8-K) — 53KB
- crbp-ex99_1.htm (EX-99.1) — 25KB
- 0001193125-26-144588.txt ( ) — 195KB
- crbp-20260401.xsd (EX-101.SCH) — 31KB
- crbp-20260401_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On April 7, 2026, the Company issued a press release announcing broad alignment with the U.S. Food and Drug Administration ("FDA") on the registration path for CRB-701, the Company's next-generation, highly stable Nectin-4 targeting antibody drug conjugate ("ADC"), in second-line head and neck squamous cell carcinoma ("HNSCC") and cervical cancer, with registrational study designs intended to support potential accelerated approval. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibits 99.1, is being furnished to the Securities and Exchange Commission (the "SEC"), and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
01 Other Events
Item 8.01 Other Events. On April 7, 2026, the Company announced broad alignment with the FDA on the registration path for CRB-701, the Company's next-generation, highly stable Nectin-4 targeting ADC, in HNSCC and cervical cancer. The agreed upon second-line registrational study designs for CRB-701 include: HNSCC: a single, randomized controlled study exploring the efficacy and safety of CRB-701 compared to physicians' choice chemotherapy with potential accelerated approval using objective response rate (ORR) as the primary endpoint and potential full approval granted on overall survival (OS) benefit. Cervical cancer: a single, randomized controlled study exploring the efficacy and safety of CRB-701 compared to physicians' choice of chemotherapy or Tivdak with potential accelerated approval using ORR as the primary endpoint and potential full approval granted on OS benefit. Continued interactions with the FDA planned to finalize the protocols and statistical analysis plans for the registrational studies.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release dated April 7, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Corbus Pharmaceuticals Holdings, Inc. Date: April 7, 2026 By: /s/ Yuval Cohen Name: Yuval Cohen Title: Chief Executive Officer